CXO and Head of R&D
Fewer surprises before reviews.
Pipeline health, value and the decisions waiting on you, without asking anyone for a deck.
A VirtuNx product · Pharma portfolio and project governance
Your pipeline decisions deserve better than a spreadsheet.
PortiVix gives pharma teams one governed place to see what is moving, what is stuck, who owns it, and what needs a decision.
- Cloud-hosted
- SSO-ready
- Capability-level RBAC
- Checksummed audit log
The cost of the status quo
Every review cycle, your most experienced people compile reports instead of making decisions. Status is a week behind. Go/kill evidence sits across drives and decks. Ownership hides in email threads. Audit evidence gets rebuilt after the fact.
The platform
One record, from the molecule to the portfolio.
Five screens your teams open every week. Scroll through them. Each one is the live product.
-
01
See the portfolio
Every project, milestone, risk and issue you own, on one dashboard. Nobody assembles a status pack.
-
02
Plan the work
Milestones, tasks and owners on one plan. The critical path to submission is drawn for you, and a slip shows up the day it happens.
-
03
Know every molecule
Stage, gate evidence, five risk frameworks and risk-adjusted value in one record, ready for the next go/kill review.
-
04
Control the risk
Every risk scored, owned and placed on one heatmap. Escalate to the PMO in one click, with the mitigation plan attached.
-
05
Prove what happened
Every change is checksummed and chained to the one before it. Verify the whole log on demand, before an inspector asks.
Platform operating model
Task-level work rolls up. Leadership decisions flow down.
Progress captured at the activity level becomes portfolio visibility, so governance is a by-product of the work, not a separate exercise.
- 01Task updateowner marks progress
- 02Workstream progressdepartment roll-up
- 03Project healthmilestones & critical path
- 04Programme riskcross-molecule view
- 05Portfolio dashboardleadership visibility
Built around pharma governance rhythms
Built for the decision moments pharma teams actually run.
PortiVix maps to the reviews your organisation already holds, and makes the evidence ready before each one.
-
Overdue work, upcoming milestones, blocked tasks, task owners, comments, risks, issues and approval queues.
Shown: Abemaciclib project plan
-
Programme health, molecule status, cross-portfolio risk, execution drift, resource pressure, financial signals and decision items.
Shown: PMO Governance
-
PTRS, Business Risk, IP Risk, API/Supply Risk, KSM scores, NPV/eNPV, commentary and go/kill evidence.
Shown: Abemaciclib molecule record
-
Filing category, submission milestones, approval evidence, audit trail, document links and date variance.
Shown: Milestone Governance
-
Material quantities, vendor records, lead times, country of origin, budget and version history.
Shown: Materials, exhibit batch readiness
One truth. Every governance moment. The same connected record powers every review, with no re-compiling between them.
Solutions
Built for the people who run the pipeline.
PMO lead
Stop compiling. Start governing.
Monthly governance, the risk heatmap and escalations in one place, current every morning.
Project manager
Every task owned. Every deadline visible.
A plan, its dependencies and its blockers that the whole team can see, so status meetings get shorter.
Built in, not bolted on
One operating model. Every report, risk and role already inside it.
- 20+
- built-in reports
- 5
- risk frameworks
- 9
- roles served
- 1
- connected operating model
Why not generic project tools?
A task tracker was never built to govern a pharma pipeline.
PortiVix is built around pharma assets, phase gates, go/kill decisions, risk scoring, NPV/eNPV, material readiness, regulatory evidence and cross-functional execution.
| Spreadsheets and generic PM toolsExcel · Asana · MS Project · Smartsheet · generic PPM | PortiVixPharma portfolio and project governance |
|---|---|
| Track tasks and deadlines. | Connect molecule strategy, phase gates, risk, finance, materials, resources, projects and audit evidence. |
| Require manual status consolidation for leadership. | Roll progress, risks, issues and milestones into portfolio and programme views. |
| Treat audit as an export or an afterthought. | Create traceability as work happens, with actor identity and change history. |
| Do not understand pharma asset decisions. | Built around molecule records, go/kill scoring, NPV/eNPV, patent fields, material readiness and regulatory evidence. |
| Flexible, but often ungoverned. | Configurable, but controlled through RBAC, approval workflows, templates, audit trail and tenant settings. |
Enterprise
Built for regulated pharma environments. Ready for enterprise scale.
Cloud-ready, SSO-ready, RBAC-driven, audit-trailed and tenant-isolated, for organisations that need secure operations and defensible records.
Cloud
Cloud-hosted with UK, EU and US region options.
Identity
SSO-ready with SAML 2.0 and OAuth 2.0.
Access
Capability-level RBAC and project-level access rules.
Security
MFA, encrypted data, a secure token model and rate limiting.
Compliance support
Audit trail, checksums, exportable logs and controls that support 21 CFR Part 11 readiness.
Deployment
Cloud, private cloud and on-premise options, subject to scoping.
Resources
Clear thinking on pharma portfolio and project governance.
Short, practical explainers for the decisions pharma leaders, PMOs, and finance teams actually make.
Insights
From Molecule Strategy to Execution
Closing the Gap in Pharma Portfolio Management
ReadInsights
When the Portfolio Is Full, What Moves?
A Full Portfolio does not eliminate choice. It makes choice more consequential. The strongest opportunities shouldn't wait for capacity. They should change what already had priority. A practical framework for evaluating new molecule…
ReadRisk
PTRS, explained for portfolio decisions
Probability of technical and regulatory success is the number every phase-gate turns on. Here is how it fits alongside business, IP, API/supply, and KSM risk.
ReadGovernance
What is pharma portfolio governance?
Why R&D-heavy pharma organisations are moving from status packs and email ownership to a governed operating model - and what that actually means day to day.
ReadFinance
eNPV vs NPV for pharma portfolios
Two molecules can share the same NPV and be worth very different amounts to your pipeline. Risk-adjusted value is why - and how leaders should use it.
ReadInsights
Welcome to the PortiVix resource hub
A quick look at how our editorial team publishes practical guides on pharma portfolio and project governance.
Read
Early access
We are onboarding a small group of pharma design partners.
PortiVix is built with pharma teams, not just for them. We work closely with a limited number of organisations to map the platform to how they actually run portfolio reviews, phase gates, and audits, before wider release.
- Shape the roadmap around your real governance rhythms
- Hands-on onboarding with a named implementation contact
- Preferential early-partner terms
See your portfolio operating model in PortiVix.
We do not start with a generic demo. We map your portfolio, molecule, project, approval and reporting workflows first, then show how PortiVix would work for your organisation.
Or write to marketing@virtunx.com